Neoantigen Peptide Development Platform
Neoantigens are produced by tumor-specific mutations and are immunogenic peptides that only exist within tumor cells. With rich experience, a large technical team, and a complete platform, our company offers comprehensive services and technical support covering every stage of therapeutic peptide development, designed to help our clients address possible barriers and challenges in the development of neoantigen peptides for rare diseases.
Introduction to Neoantigen Peptides
Neoantigen peptides are produced by the deletion, insertion, or substitution of single amino acids, ranging from 8 to 50 amino acids. Short peptides are 8 to 12-mers in size and can be used in cytotoxic T-cell stimulation tests. Long neoantigen peptides are 17 to 40-mers in size and can be combined with short neoantigen peptides and other functional short peptides. Neoantigen peptides are usually presented on the surface of cancer cells due to mutation events in cancer cells, also known as tumor-specific antigens (TSA), and play an important role in tumor immunotherapy.
Challenges of Neoantigen Peptide Development
T cells play an important role in recognizing and killing specific tumor cells, and T cells that recognize tumor neoantigens may have high affinity. Neoantigen peptides have broad application prospects in allogeneic/autologous T-cell treatments (ATCT) and personalized cancer vaccine (PCV) development. However, the development of neoantigen peptides has certain difficulties:
The synthesis of long neoantigen peptides larger than 20aa is more difficult.
The more hydrophobic peptides are difficult to synthesize.
The high production of neoantigen peptides is difficult.
The isoelectric point (pI) of neoantigen peptides increases the difficulty of synthesis.
With years of experience, our company employs top experts to build and improve technology platforms, including microwave, solid phase peptide synthesis (SPPS), and liquid phase peptide synthesis (LPPS) technology platforms to support neoantigen peptides development to meet your various needs in rare disease research.
- Neoantigen Prediction and Screening
Use the existing database to screen neoantigens and predict neoantigens with high sensitivity, including but not limited to:
- Next-generation sequencing (NGS) is used to predict and select novel tumor antigens.
- Exome sequencing and/or transcriptome sequencing are used to efficiently characterize DNA and/or RNA.
- Bioinformatics tools are used to predict the presentation of mutant peptides to aid in neoantigen selection.
- Immunogenicity Validation of Neoantigen Peptides
To ensure that candidate neoantigens can be used in downstream experiments, we provide T cell activation assays, such as ELISPOT, ELISA, or flow cytometry, for verification of neoantigen synthetic peptides.
- Quality Control
Our company has a complete chromatography and mass spectrometry platform that can provide QC analysis of peptides, including but not limited to:
- Amino Acid Analysis
- Net Peptide Content
- Residual Solvents
- Elemental Analysis
- Stability Testing
- Solubility Testing
- NMR Analysis
- LC-ESI-MS Analysis
In addition to the above-mentioned neoantigen peptide development services, we can also provide pre-clinical testing services according to your requirements, providing you with a one-stop solution to accelerate your rare disease research.
Why Choose Us?
- Providing standardized upstream platform solutions
- Timely project reporting and after-sales service
- One-stop platform with an experienced technical team
- Careful design and transparent operation process
- Ability to customize products and services
- Expertise and experience in the industry
With extensive experience in rare disease therapy research and development, our company's neoantigen peptide development is a simplified workflow by a group of specially trained and professional scientists. We are pleased to use our advanced platform to offer the best service and the most qualified products to satisfy each demand from our customers. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Ye, Linda, et al. "The current lung cancer neoantigen landscape and implications for therapy." Journal of Thoracic Oncology 16.6 (2021): 922-932.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.